Clinical Trial Update: Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating tralokinumab for atopic dermatitis sponsored by the University of Zurich has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Tralokinumab (tralokinumab)

Snippet

Sponsor: University of Zurich | Conditions: Atopic Dermatitis | Phase 2, Phase 3 | Status: TERMINATED